CA3227139A1 - Methods for inhibiting the progression of oxidative retinal diseases - Google Patents

Methods for inhibiting the progression of oxidative retinal diseases Download PDF

Info

Publication number
CA3227139A1
CA3227139A1 CA3227139A CA3227139A CA3227139A1 CA 3227139 A1 CA3227139 A1 CA 3227139A1 CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A1 CA3227139 A1 CA 3227139A1
Authority
CA
Canada
Prior art keywords
day
patient
progression
ester
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227139A
Other languages
English (en)
French (fr)
Inventor
Karsten Schmidt
Mikhail Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biojiva LLC
Original Assignee
Biojiva LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biojiva LLC filed Critical Biojiva LLC
Publication of CA3227139A1 publication Critical patent/CA3227139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3227139A 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases Pending CA3227139A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163224690P 2021-07-22 2021-07-22
US202163224674P 2021-07-22 2021-07-22
US202163224679P 2021-07-22 2021-07-22
US63/224,679 2021-07-22
US63/224,674 2021-07-22
US63/224,690 2021-07-22
PCT/US2022/038072 WO2023004151A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Publications (1)

Publication Number Publication Date
CA3227139A1 true CA3227139A1 (en) 2023-01-26

Family

ID=84979648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227139A Pending CA3227139A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Country Status (8)

Country Link
US (1) US20250099415A1 (enExample)
EP (1) EP4373479A4 (enExample)
JP (1) JP2024526939A (enExample)
KR (1) KR20240036651A (enExample)
AU (1) AU2022313207A1 (enExample)
CA (1) CA3227139A1 (enExample)
IL (1) IL310210A (enExample)
WO (1) WO2023004151A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024049497A1 (en) * 2022-09-02 2024-03-07 Biojiva Llc Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
WO2009018333A2 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
US20100324138A1 (en) * 2007-10-29 2010-12-23 Bazan Nicolas G Lipoxin A4 Protection for Retinal Cells
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
EP3950649A1 (en) * 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
EP3880194A4 (en) * 2018-11-15 2022-11-09 Retrotope, Inc. DEUTERED COMPOUNDS, COMPOSITIONS AND USES

Also Published As

Publication number Publication date
IL310210A (en) 2024-03-01
EP4373479A1 (en) 2024-05-29
JP2024526939A (ja) 2024-07-19
AU2022313207A1 (en) 2024-02-29
US20250099415A1 (en) 2025-03-27
WO2023004151A1 (en) 2023-01-26
EP4373479A4 (en) 2025-11-05
KR20240036651A (ko) 2024-03-20

Similar Documents

Publication Publication Date Title
EP3735963B1 (en) Self-emulsifying composition of omega-3 fatty acid
RU2709612C2 (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
JP7761371B2 (ja) 対象におけるマイトファジーを改善するための方法
KR101383006B1 (ko) 고중성지방혈증 치료 방법
CN107405326A (zh) ω3脂肪酸的自乳化组合物
UA76108C2 (en) Use of therapeutic combination of fatty acids
EP3763364A1 (en) Self-emulsifying composition of omega-3 fatty acid
KR20010022786A (ko) 당뇨병 치료를 위한 방법 및 조성물
US11351143B1 (en) Methods of treating amyotrophic lateral sclerosis
WO2003072111A2 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
BRPI0619598A2 (pt) composição de emulsão intravenosa de ácido graxo essencial e métodos de administração da mesma
WO2023023397A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
CA3227139A1 (en) Methods for inhibiting the progression of oxidative retinal diseases
US20040014712A1 (en) Blood lipid ameliorant composition
US20230255917A1 (en) Methods of treating amyotrophic lateral sclerosis
KR20180010181A (ko) Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
MX2007010493A (es) Compuestos que tienen propiedades reductoras de lipidos.
CN118019529A (zh) 抑制氧化性视网膜疾病进展的方法
US20240091187A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
JP2025507361A (ja) 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法
AU2005265998A1 (en) Compositions and methods for smoking cessation
KR20260010331A (ko) L-세린의 리포좀 제형 및 이의 제조 방법
JP2025506208A (ja) Ａｌｓ治療のための相乗的併用療法
JPS6011422A (ja) 抗筋ジストロフイ−症剤
EP4287835A2 (en) Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof